Alexander Jethwa

Alexander Jethwa

Auto-generated profile, based on publicly available information

Alexander Jethwa

Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2015 in Leukemia
Verified
Journal Article
Closed access
CBC J Blume
C J Blume
AHA Hotz-Wagenblatt
A Hotz-Wagenblatt
JHJ Hüllein
J Hüllein
LSLeopold Sellner
Leopold Sellner
AJA Jethwa
A Jethwa
TZT Zenz
T Zenz

11 December 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDSascha Dietrich
Sascha Dietrich
MOMałgorzata Oleś
Małgorzata Oleś
JLJunyan Lu
Junyan Lu
LSLeopold Sellner
Leopold Sellner
SASimon Anders
Simon Anders
TZThorsten Zenz
Thorsten Zenz
As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non–BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.

9 June 2016 in Blood
Verified
Journal Article
Closed access
PDF file
SDSascha Dietrich
Sascha Dietrich
APAndreas Pircher
Andreas Pircher
VEVolker Endris
Volker Endris
FPFrédéric Peyrade
Frédéric Peyrade
CWClemens-Martin Wendtner
Clemens-Martin Wendtner
TZThorsten Zenz
Thorsten Zenz
The activating mutation of the BRAF serine/threonine protein kinase (BRAF V600E) is the key driver mutation in hairy cell leukemia (HCL), suggesting opportunities for therapeutic targeting. We analyzed the course of 21 HCL patients treated with vemurafenib outside of trials with individual dosing regimens (240-1920 mg/d; median treatment duration, 90 days). Vemurafenib treatment improved blood counts in all patients, with platelets, neutrophils, and hemoglobin recovering within 28, 43, and 55 days (median), respectively. Complete remission was achieved in 40% (6/15 of evaluable patients) and median event-free survival was 17 months. Response rate and kinetics of response were independent of vemurafenib dosing. Retreatment with vemurafenib led to similar response patterns (n = 6). Pharmacodynamic analysis of BRAF V600E downstream targets showed that vemurafenib (480 mg/d) completely abrogated extracellular signal-regulated kinase phosphorylation of hairy cells in vivo. Typical side effects also occurred at low dosing regimens. We observed the development of acute myeloid lymphoma (AML) subtype M6 in 1 patient, and the course suggested disease acceleration triggered by vemurafenib. The phosphatidylinositol 3-kinase hotspot mutation (E545K) was identified in the AML clone, providing a potential novel mechanism for paradoxical BRAF activation. These data provide proof of dependence of HCL on active BRAF signaling. We provide evidence that antitumor and side effects are observed with 480 mg vemurafenib, suggesting that dosing regimens in BRAF-driven cancers could warrant reassessment in trials with implications for cost of cancer care. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Low doses of the BRAF inhibitor vemurafenib are highly effective in refractory hairy cell leukemia. Abrogation of BRAF V600E–induced signaling was consistently seen with 240 mg of vemurafenib twice daily.

5 November 2014 in Leukemia
Verified
Journal Article
Closed access
GRG D Te Raa
G D Te Raa
IDI A M Derks
I A M Derks
VNV Navrkalova
V Navrkalova
ASA Skowronska
A Skowronska
PMPerry D Moerland
Perry D Moerland
EEEric Eldering
Eric Eldering

6 December 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MSMartina Seiffert
Martina Seiffert
SDSascha Dietrich
Sascha Dietrich
AJAlexander Jethwa
Alexander Jethwa
HGHanno Glimm
Hanno Glimm
PLPeter Lichter
Peter Lichter
TZThorsten Zenz
Thorsten Zenz
There is remarkable heterogeneity in the clinical course and biological characteristics of patient subgroups with chronic lymphocytic leukemia (CLL). Mutations of key tumor suppressors (ATM, miR-15a/16-1 and TP53) have been identified in CLL, and these aberrations are important "drivers" of the disease and some of its clinical characteristics. While some mutations are associated with poor outcome [particularly del(17p) and TP53 mutation], others are linked to a favorable clinical course [e.g. del(13q) as sole aberration]. In addition to genetic aberrations, antigen drive and microenvironmental interactions contribute to the pathogenesis of CLL. How the genetic aberrations impact on the process of antigen drive or microenvironmental interactions is currently unclear. Our improved understanding of the biology and clinical course of specific genetic subgroups is beginning to be translated into more specific and targeted treatment approaches. As a result, genetic subgroups are treated in distinct protocols. This review summarizes the contribution of the microenvironment and the most important genetic aberrations in CLL and how our improved knowledge of the biology of CLL may translate into improved treatment results.

27 August 2013 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AJAlexander Jethwa
Alexander Jethwa
JHJennifer Hüllein
Jennifer Hüllein
TSTatjana Stolz
Tatjana Stolz
CBCarolin Blume
Carolin Blume
LSLeopold Sellner
Leopold Sellner
TZThorsten Zenz
Thorsten Zenz
Summary: Recurrent gene mutations contribute to the pathogenesis of chronic lymphocytic leukaemia (CLL). We developed a next‐generation sequencing (NGS) platform to determine the genetic profile, intratumoural heterogeneity, and clonal structure of two independent CLL cohorts. TP53, SF3B1, and NOTCH1 were most frequently mutated (16·3%, 16·9%, 10·7%). We found evidence for subclonal mutations in 67·5% of CLL cases with mutations of cancer consensus genes. We observed selection of subclones and found initial evidence for convergent mutations in CLL. Our data suggest that assessment of (sub)clonal structure may need to be integrated into analysis of the mutational profile in CLL.